Skip to content

Advertisement

  • Letter to the Editor
  • Open Access

Identification of patient-derived glioblastoma stem cell (GSC) lines with the alternative lengthening of telomeres phenotype

  • 1,
  • 2,
  • 1,
  • 2,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 2Email authorView ORCID ID profile
Acta Neuropathologica Communications20197:76

https://doi.org/10.1186/s40478-019-0732-4

  • Received: 13 March 2019
  • Accepted: 3 May 2019
  • Published:

Glioblastoma multiforme (GBM) is an aggressive brain tumor with a poor overall prognosis. Current standard of care involves surgical resection followed by adjuvant treatment with radiation (RT), temozolomide, and tumor treating fields (TTF) [13]. Despite this aggressive treatment modality, median overall survival is approximately 15 months. Telomeres are terminal DNA elements found at eukaryotic chromosomal ends consisting of hexagonal repeats of (TTAGGG)n which are essential for maintaining genomic stability [1]. To maintain telomere length and circumvent the end-replication problem, most cancer cells express telomerase [8]. Telomerase is composed of two subunits: a catalytic component with reverse-transcriptase activity encoded by the gene TERT, and an 11 base-pair RNA template encoded by the gene TERC [11]. Mutations in the promoter region for TERT occur in approximately 60–80% of GBM, leading to increased telomerase activity and enabling replicative immortality [10]. A defining feature of anaplastic astrocytomas and a small fraction of secondary GBM, is activation of a telomerase-independent alternative lengthening of telomeres (ALT) mechanism, driven by homologous recombination (HR) machinery [7]. ALT tumors can readily be detected by assaying for the presence of extrachromosomal telomeric DNA C-Circles (CCs) via qPCR or ALT-associated telomere foci by FISH on pathological specimens [6]. ALT+ high grade glioma (HGG) are enriched in tumors with loss of function mutations in ATRX (alpha-thalassemia/mental retardation X-linked) and less commonly, SMARCAL1. When these chromatin remodeling genes are inactivated, the resultant replication stress and aberrant HR at telomeres is hypothesized to lead to ALT [2]. Mutations in both ATRX and SMARCAL1 are mutually exclusive with TERT promoter mutations suggesting functional redundancy between these two mechanistic pathways [3, 4].

Here, we sought to identify and characterize ALT+ GBM by screening through a panel of 24 patient-derived GBM stem cell lines (GSCs). We tested for ALT using a novel qPCR method that measures both telomere content (TC), which is indicative of overall telomere length, and DNA C-Circles (CCs), which are specific and quantifiable markers for ALT activity [9]. Telomerase expression was assessed by quantifying mRNA levels of TERT using whole transcriptome sequencing. ATRX protein expression was measured by immunoblotting.

Of the 24 GSCs that were tested, 2 were found to be ALT+ (8.3%), GS 5–22 and GS 8–18. These 2 cell lines have significantly elevated DNA CC content (P < 0.001, t-test) and telomere content (p < 0.001, t-test) relative to other GSCs (Fig. 1a and b). Furthermore, both GS 5–22 and GS 8–18 lack detectable full length ATRX protein upon immunoblot analysis (Fig. 1c). Whole transcriptome sequencing data (available for 22 of 24 GSCs) identified mRNA expression of TERT to be negligible in the two ALT+ GSCs, indicating absence of telomerase activity, whereas the remaining GSCs all had some quantifiable level of TERT expression (p = 0.0087, Mann-Whitney test) (Fig. 1d). Importantly, both GS 5–22 and GS 8–18 were derived from patients with secondary glioblastoma with concurrent IDH mutations. Also, p53 immunostaining was positive in both ALT+ GSCs (data not shown) corroborating p53 loss of function and mutant IDH along with ATRX loss as important in the development of ALT+ GBM. GS 5–22 and 8–18 display longer doubling times in vitro, 5 days and 8 days, respectively, relative to ATRX-intact TERT-positive GSCs which have a mean doubling time of ~ 3–4 days. We injected GS 522 cells intracranially into athymic mice to evaluate their ability to generate stable xenografts, and saw tumors form within 1 months’ time (Fig. 1e).
Fig. 1
Fig. 1

ALT+ GSCs were detected by quantifying telomere (a) and DNA C-Circle content (b) in a panel of 24 cell lines. Using a threshold cut-off value of 0.5 (dashed line) for telomere content and CCs, 2 ALT+ GSCs were identified, GS 8–18 and GS 5–22. Both GS 5–22 and GS 8–18 lack detectable ATRX protein (c). Additionally, these cell lines have negligible mRNA expression for TERT (d), indicating lack of telomerase activity. U-2 OS, a commercially available ALT+ osteosarcoma cell line which is ATRX mutant was used as a positive control for ALT and negative control for ATRX immunoblotting. Conversely, TS 603 and TS 543 which are known ATRX wild-type GSCs, were used as negative controls for ALT and positive controls for ATRX immunoblotting. GS 5–22 cells, stably expressing the luciferase reporter, were injected intracranially into nude mice and formed tumors within 4 weeks (e)

To date, only 2 ALT+ glioma cell lines have been documented (TG-20 and JHH-GBM14) [5, 12], however in these prior studies ALT was assayed for by immunofluorescent detection of telomere/PML body foci and lack of telomerase activity via the telomerase repeat amplification protocol (TRAP) assay. We report here that detection of DNA CCs via qPCR and mRNA quantification of TERT are also usable biomarkers that can reliably detect ALT and may be more applicable in a clinical setting as both assays require minute amounts of DNA and RNA. In conclusion, identification of these ALT+ GSCs will enable future explorations of the mechanisms and biology of the ALT phenotype, and will serve as pre-clinical models to test novel chemotherapeutic agents in an effort to improve outcomes in a subset of high-grade gliomas and secondary GBM.

Declarations

Acknowledgements

Not applicable.

Funding

This study was supported in part by the Radiological Society of North America (RSNA) Prince Research Resident Grant (2018–2019).

Availability of data and materials

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Authors’ contributions

AF conceived the experiments and took lead in writing the manuscript. JY, VS, RE, CD, CA, SD, DI all aided in the experimental design and analysis of data. JH and EPS developed the theoretical framework, supervised the project and experiments, and helped revise the manuscript.All authors read and approved the final manuscript.

Ethics approval and consent to participate

Yes, reviewed by the IRB. Acquisition of these human cell lines was covered under an institutional protocol “LAB04–0001,” with full informed consent obtained from each person.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
University of Texas MD Anderson Cancer Center, Houston, TX, USA
(2)
NYU Langone Health, New York, NY, USA

References

  1. Blackburn EH (1991) Structure and function of telomeres. Nature 350:569–573. https://doi.org/10.1038/350569a0 View ArticlePubMedGoogle Scholar
  2. Brosnan-Cashman JA, Graham MK, Heaphy CM (2018) Genetic alterations associated with ALTered telomeres. Oncotarget 9:33739–33740. https://doi.org/10.18632/oncotarget.26111 View ArticlePubMedPubMed CentralGoogle Scholar
  3. Diplas BH, He X, Brosnan-Cashman JA, Liu H, Chen LH, Wang Z, Moure CJ, Killela PJ, Loriaux DB, Lipp ES, Greer PK, Yang R, Rizzo AJ, Rodriguez FJ, Friedman AH, Friedman HS, Wang S, He Y, McLendon RE, Bigner DD, Jiao Y, Waitkus MS, Meeker AK, Yan H (2018) The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nat Commun 9:2087. https://doi.org/10.1038/s41467-018-04448-6 View ArticlePubMedPubMed CentralGoogle Scholar
  4. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279 View ArticlePubMedPubMed CentralGoogle Scholar
  5. Heaphy CM, Schreck KC, Raabe E, Mao XG, An P, Chu Q, Poh W, Jiao Y, Rodriguez FJ, Odia Y, Meeker AK, Eberhart CG (2013) A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathol 126:607–608. https://doi.org/10.1007/s00401-013-1174-x View ArticlePubMedGoogle Scholar
  6. Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, Pickett HA, Reddel RR (2009) DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 27:1181–1185. https://doi.org/10.1038/nbt.1587 View ArticlePubMedGoogle Scholar
  7. Henson JD, Neumann AA, Yeager TR, Reddel RR (2002) Alternative lengthening of telomeres in mammalian cells. Oncogene 21:598–610. https://doi.org/10.1038/sj.onc.1205058 View ArticlePubMedGoogle Scholar
  8. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific Association of Human Telomerase Activity with Immortal Cells and Cancer. Science 266:2011–2015. https://doi.org/10.1126/science.7605428 View ArticleGoogle Scholar
  9. Lau LM, Dagg RA, Henson JD, Au AY, Royds JA, Reddel RR (2013) Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Res 41:e34. https://doi.org/10.1093/nar/gks781 View ArticlePubMedGoogle Scholar
  10. Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126:931–937. https://doi.org/10.1007/s00401-013-1163-0 View ArticlePubMedGoogle Scholar
  11. Nugent CI, Lundblad V (1998) The telomerase reverse transcriptase: components and regulation. Genes Dev 12:1073–1085View ArticlePubMedGoogle Scholar
  12. Silvestre DC, Pineda JR, Hoffschir F, Studler JM, Mouthon MA, Pflumio F, Junier MP, Chneiweiss H, Boussin FD (2011) Alternative lengthening of telomeres in human glioma stem cells. Stem Cells 29:440–451. https://doi.org/10.1002/stem.600 View ArticlePubMedGoogle Scholar
  13. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z (2015) Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543. https://doi.org/10.1001/jama.2015.16669 View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement